Prevalence of clinical and laboratory characteristics at the onset of disease and during followup.
| Clinical and Laboratory Characteristics | Presence at Onset, n (%) | Cumulative Prevalence, n (%) |
|---|---|---|
| Venous thrombosis | 28 (20.7) | 57 (42.2) |
| Peripheral arterial thrombosis | 6 (4.4) | 12 (8.9) |
| Stroke (arterial) | 10 (7.4) | 32 (23.7) |
| Brain microinfarcts/TIA | 1 (0.74) | 14 (10.4) |
| Epilepsy/seizures | 2 (1.5) | 19 (14.1) |
| Headache/migraine | 6 (4.4) | 34 (25.2) |
| Pulmonary emboli | 7 (5.2) | 16 (11.8) |
| APS nephropathy | 1 (0.74) | 6 (4.4) |
| Arthralgia | 25 (18.5) | 67 (49.6) |
| Arthritis | 9 (6.7) | 21 (15.5) |
| Livedo reticularis | 2 (1.5) | 48 (35.5) |
| Malar rash (butterfly rash) | 8 (5.9) | 21 (15.5) |
| Mucosal ulcers | 6 (4.4) | 15 (11.1) |
| Photosensitivity | 8 (5.9) | 20 (14.8) |
| Fetal loss | 23 (23)* | 40 (40)* |
| Hemolytic anemia | 2 (1.5) | 22 (16.3) |
| Thrombocytopenia | 5 (3.7) | 20 (14.8) |
| Leukopenia | 1 (0.74) | 40 (29.6) |
↵* Percentage out of the total of female patients (n = 100). TIA: transient ischemic attack; APS: antiphospholipid syndrome.